Microarray Ltd is a UK-based specialist wound healing company. Founded in 2000 as a spin-out from Manchester Universities, the company is now privately owned and has office and laboratory facilities at Colworth Science Park and Cranfield University. The company has wide ranging expertise in the fields of wound dressing product development, marketing and sales; electrochemistry and diagnostic sensor technologies; biochemistry, oxygen and iodine chemistry; enzymology, immunology and inflammation. Current research and development activities are concentrated on innovative, electrochemically-active wound dressings for the treatment of chronic wounds and on wound care diagnostics. Microarray owns and continues to develop new intellectual property in its specialist fields. It works independently and with expert academic and industrial partners.
11-50 Employees
Working industry
Research
Type of company
-
Specialised areas
Research
Some frequent questions that have been asked about Microarray Limited
How many employees does Microarray Limited approximately have?
As of the latest available information Microarray Limited has around 11-50 employees worldwide.
In which industries does Microarray Limited mainly work?
The company Microarray Limited has it's main focus in the industries of Research
Check out some interesting alternative companies to Microarray Limited
Applied Microarrays
Tempe, United States
101-250 Employees
2007
Applied Microarrays (“AMI”) was founded in 2006 by CEO Alastair Malcolm, with the business model of manufacturing Point-of-Care and High Throughput DNA and protein arrays whose custom bio-content is developed by AMI’s customers. The array manufacturing equipment from GE has unique features enabling quality, accuracy and repeatability not available in tools sold on the general market. In October 2021 AMI was acquired by SCHOTT MINIFAB, a world leading microfluidic diagnostics and lifescience company. Combined, AMI and SCHOTT MINIFAB have a team of over 300 specialists with manufacturing sites in Europe, Australia and USA. Accordingly we treat our customer engagements with quality systems that will enable their products to be accepted successfully in regulated markets.
Arrayit
Sunnyvale, United States
1-10 Employees
1993
Arrayit customers include the brightest minds in university laboratories, government laboratories, biotechnology companies, life sciences companies, clinical laboratories, pharmaceutical companies and hospitals worldwide. Arrayit microarray technology empowers scientists with the tools required to make important discoveries and change the world. Arrayit microarray technology products and services are featured in more than 6,000 peer-reviewed scientific publications, for the ultimate in scientific credibility. Arrayit microarray technology miniaturizes traditional tests by 100-fold or more, which reduces manufacturing and personnel costs, increases testing throughput and packs tremendous scientific content into each research test. Arrayit microarray technology affords life sciences researchers with the tools required to identify these markers, leading potentially to transformative healthcare advances. Arrayit offers a full suite of microarray-based products and services to empower researchers with the tools required to make next generation discoveries for human kind. Arrayit sets the standard in the microarray industry with ArrayIt® Brand DNA Microarrays. Arrayit sets the standard for the microarray industry with ArrayIt® brand Purification Products.
INTER-ARRAY by fzmb GmbH
Bad Langensalza, Germany
11-50 Employees
1994
INTER-ARRAY combines bioanalytics with state-of-the-art microtechnologies, especially in the field of high precision microdispensing. INTER-ARRAY is partner of companies and institutions in the fields of medicine and medical technology, diagnostics, environmental analysis and pharmaceutical development. INTER-ARRAY is part of fzmb GmbH, Research Center for Medical Technology and Biotechnology (Germany), which has extensive experience in immunochemistry, biomedicine and bioanalytics. INTER-ARRAY supports its partners in all microarray development stages, from feasibility study, optimization, verification and validation to pilot production. INTER-ARRAY offers solutions for multiparameter assay development and validation for any application in human and veterinary diagnostics and life sciences. INTER-ARRAY is a full service provider in the life science sector with its protein and antibody, molecular, microbiology, bioconjugation and surface technology labs. INTER-ARRAY Genotyping Kits allow DNA-based detection of antibiotic resistance genes, virulence genes and pathogenicity markers of different multi-resistant pathogens by simple and quick assignment of unknown isolates to known strains within hours. Founded in 1994 by biotechnologists, engineers and physicians, the ISO-certified company today develops and manufactures innovative, high-quality diagnostic products for laboratory and point-of-care applications.
Arrayjet
City of Edinburgh, United Kingdom
11-50 Employees
2000
Arrayjet is a leading microarray company that provides solutions to researchers and development groups across academia, biotechnology, pharma and diagnostics. Arrayjet Ltd was established in 2000 with private equity from Archangel Investors Ltd and the Scottish Government. Arrayjet is at the global forefront of this field and has installed instruments throughout 5 continents since commercialisation in 2006. In 2011 Arrayjet Advance™ was launched to offer contract research and contract manufacturing services. In 2021 we launched operations in the USA with the formation of Arrayjet Inc. The help us assess whether our services and products are reaching our intended audience in an effective way we make use of marketing platforms such as Google Ads and LinkedIn.
Io-Cyte
Bradford, United Kingdom
1-10 Employees
2019
Millions of patients have to live with wounds that do not heal normally, taking months or years to heal. Their numbers are continually growing, their wounds are complex to assess and continually changing. This creates an obstacle course for practitioners working in increasingly constrained health care systems and trying to select the right treatment at the right time. Io-Cyte exists to provide innovative treatments for healing the wound that can be applied in the patient’s home or doctor’s office. Research has told us more than ever about the multiple barriers to healing, such as biofilms, local infection and chronic inflammation, however deciding what is the main obstacle facing a particular wound at any one time is far from straightforward. Io-Cyte are developing dressings that combat multiple healing barriers at once to give the best chance of forming a healthy wound base for healing. The company formed in October 2019 when we identified the potential wound-healing benefits from research in a biomaterials laboratory specialising in biocompatible and absorbent fibre materials. Chris Marsden (Managing Director) has over 25 years’ experience in medical devices, with Zimmer, 3M Healthcare, Johnson & Johnson and other companies. At Johnson & Johnson he was project manager for the development and launch of a bioactive dressing before moving to marketing and commercial roles. His commercial roles include product management, head of marketing role and key account management for US wound care customers. He has been closely involved with design and management of a number of clinical trials in wound healing and surgery. Prior to joining Io-Cyte, Chris was sales and marketing director at Xiros. David Farrar (Research Manager) also Head of New Technologies for Xiros Ltd. Prior to joining Io-Cyte/Xiros David worked for Smith & Nephew for 30 years in a variety of R&D roles but latterly heading up the company’s Biomaterials research programme at its global research centre in York.
MagArray
Milpitas, United States
11-50 Employees
2005
MagArray was founded in 2005 by Stanford professors who adapted magnetic sensing technology from the computer disk drive industry for use in medical diagnostics. MagArray technology builds upon the giant magnetoresistive (GMR) nanosensors used as read head elements in computer hard drives to detect biomolecules or biomarkers labeled with magnetic nanoparticles. Using this pioneering technology, MagArray has developed a simple, ultra-sensitive, multiplex immunoassay system. MagArray previously received early stage funding and support from the National Cancer Institute (NCI) in the U.S. MagArray develops and deploys medical diagnostics with a technology that brings new levels of sensitivity and ease of use to immunoassays through the innovative application of magnetic nanosensors. Highly sensitive, the system overcomes limitations of other common clinical analysis technologies to deliver significant advantages to both laboratories and clinical assay designers. Our diagnostic technology is uniquely positioned to help the healthcare community deliver better outcomes through improved early detection of disease, minimization of over-diagnoses, and enhanced disease progression monitoring in oncology, cardiology, infectious disease, allergy, inflammatory disease, and other areas. Founded by Stanford professors who adapted magnetic sensing technology from the computer disk drive industry, MagArray develops simple, ultra-sensitive, multiplex immunoassay systems.